bf/NASDAQ:ALRN_icon.jpeg

NASDAQ:ALRN

Aileron Therapeutics

  • Stock

USD

Last Close

1.93

10/01 21:00

Market Cap

66.06M

Beta: 2.01

Volume Today

63.39K

Avg: 53.55K

PE Ratio

−1.68

PFCF: −1.64

OverviewFinancialsAPI

    Description

    Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -2-1.5-1-0.52020-12-312022-05-052023-11-072024-04-152024-11-08

    Revenue (Estimate*)

    20K40K60K80K100K120K140K2020-12-312022-05-052023-11-072024-04-152024-11-08

    *Estimate based on analyst consensus